Afatinib Dimaleate

CHEMBL2105712 Phase 4 अनुमोदित Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

718.1 g/mol

LogP

—

Phase

4

The dimaleate salt form of afatinib, a tyrosine kinase inhibitor that irreversibly blocks EGFR and HER2 receptors involved in driving certain cancers. This formulation improves the drug's stability and absorption while delivering the same targeted anti-cancer activity as the parent compound.

आणविक भार

718.1000 g/mol

TPSA

238.00 Å²

चिकित्सीय क्षेत्र

अग्नाशय कैंसर अल्ज़ाइमर रोग इंफ्लेमेटरी बाउल डिज़ीज़ एंडोमेट्रियोसिस ओवेरियन कैंसर कोलोरेक्टल कैंसर क्रॉनिक ऑब्सट्रक्टिव पल्मोनरी डिज़ीज़ (COPD) क्रॉनिक किडनी डिज़ीज़ गैस्ट्रोइसोफेजियल रिफ्लक्स रोग थायरॉइड कैंसर नॉन-अल्कोहलिक फैटी लिवर डिज़ीज़ नॉन-स्मॉल सेल लंग कैंसर पार्किंसन रोग प्रोस्टेट कैंसर मूत्राशय कैंसर मेलानोमा लिम्फोमा ल्यूकेमिया श्वसन रोग संक्रामक रोग स्तन कैंसर हृदय-संवहनी रोग

क्रिया का तंत्र

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

2D संरचना

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O

InChI

InChI=1S/C24H25ClFN5O3.2C4H4O4/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15;2*5-3(6)1-2-4(7)8/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29);2*1-2H,(H,5,6)(H,7,8)/b4-3+;2*2-1-/t16-;;/m0../s1

Molecular Formula

C32H33ClFN5O11

HBD / HBA

6 / 16

घूर्णनीय बंधन

12

भारी परमाणु

50

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

The dimaleate salt form of afatinib, a tyrosine kinase inhibitor that irreversibly blocks EGFR and HER2 receptors involved in driving certain cancers. This formulation improves the drug's stability and absorption while delivering the same targeted anti-cancer activity as the parent compound.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Afatinib Dimaleate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105712. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 15606394. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

रोगी-अनुकूल जानकारी खोज रहे हैं?

Afatinib Dimaleate PillFYI पर

संरचना

त्वरित डेटा

सूत्र: C32H33ClFN5O11

बाहरी लिंक

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.